Role of p-ERK1/2 in Benign Prostatic Hyperplasia during Hyperinsulinemia
5 January 2019
Purpose: Using a rat model of hyperinsulinemia, the present study investigated the role of p-ERK1/2 in benign prostatic hyperplasia (BPH).
Materials and Methods: Forty male Sprague-Dawley rats were randomly selected and assigned to four groups: high fat diet (HFD)+BPH (n=10), HFD (n=10), BPH (n=10), and control (n=10) groups. Hyperinsulinemia was induced by HFD feeding, while BPH was induced using testosterone propionate. Plasma glucose, plasma insulin and bodyweight were examined weekly. Immunohistochemistry (IHC) and western blot analysis were used to analyze the expression of ERK1/2 and p-ERK1/2 in rat prostates.
Results: Plasma glucose and plasma insulin levels were significantly greater in the HFD+BPH and HFD groups, when compared to the other two groups (P<0.05). Prostate weights were significantly greater in the HFD+BPH, HFD and BPH groups, than in the control group (P<0.05). IHC and western blot analysis revealed that p-ERK1/2 expression was greater in the HFD+BPH group than in the other three groups (P<0.05).
Conclusion: Androgens plus a hyperinsulinemic condition induced by HFD can result in prostatic cell hyperplasia, and this mechanism may be correlated to the upregulation of p-ERK1/2. Further investigations of this possibility are required.
Li SH, Yang QF, Zuo PY, Liu YW, Liao YH, Liu CY. Prostate volume growth rate changes over time: Results from men 18 to 92 years old in a longitudinal community-based study. J Huazhong Univ Sci Technolog Med Sci 2016;36:796-800.
Zeng XT, Su XJ, Li S, Weng H, Liu TZ, Wang XH. Association between SRD5A2 rs523349 and rs9282858 Polymorphisms and Risk of Benign Prostatic Hyperplasia: A Meta-Analysis. Front Physiol 2017;12:688.
Robinson D, Garmo H, Holmberg L, Stattin P. 5-α reductase inhibitors, benign prostatic hyperplasia and risk of male breast cancer. Cancer Causes Control 2015;26:1289-97.
Schauer IG, Rowley DR.The functional role of reactive stroma in benign prostatic hyperplasia. Differentiation 2011;82:200-10.
Paola Lucia Minciullo, Antonino Inferrera, Michele Navarra, Gioacchino Calapai, Carlo Magno, Sebastiano Gangemi. Oxidative Stress in Benign prostatic hyperplasia: a systematic review. Urol Int 2015;94:249-254.
Bostanci Y, Kazzazi A, Momtahen S, Laze J, Djavan B. Sci Rep. Correlation between benign prostatic hyperplasia and inflammation. Curr Opin Urol 2013;23:5-10.
Saito M, Tsounapi P, Oikawa R, Shimizu S, Honda M, Sejima T, Kinoshita Y, Tomita S. Prostatic ischemia induces ventral prostatic hyperplasia in the SHR; possible mechanism of development of BPH. Sci Rep 2014;4:3822.
Vignozzi L, Rastrelli G, Corona G, Gacci M, Forti G, Maggi M. Benign prostatic hyperplasia: a new metabolic disease? J Endocrinol Invest 2014;37:313-22.
Issa MM, Regan TS. Medical therapy for benign prostatic hyperplasia-present and future impact. Am J Manag Care 2007;13:S4-S9.
Qu X, Huang Z, Meng X, Zhang X, Dong L, Zhao X. Prostate volume correlates with diabetes in elderly benign prostatic hyperplasia patients. Int Urol Nephrol 2014;46:499-504.
Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol 2007;51:199-203; discussion 204-206.
Vikram A, Jena G, Ramarao P. Insulin-resistance and benign prostatic hyperplasia: the connection. Eur J Pharmacol 2010;641:75-81.
Vikram A, Jena GB, Ramarao P. Increased cell proliferation and contractility of prostate in insulin resistant rats: linking hyperinsulinemia with benign prostate hyperplasia. Prostate 2010;70:79-89.
Vikram A, Jena G, Ramarao P. Pioglitazone attenuates prostatic enlargement in diet-induced insulin-resistant rats by altering lipid distribution and hyperinsu-linemia. Br J Pharmacol 2010;161:1708-21.
Jiang ZY, Lin YW, Clemont A, Feener EP, Hein KD, Igarashi M, Yamauchi T, White MF, King GL. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest 1999;104:447-457.
Biolly B, Vercouter-Edouart AS, Hondermark H, Nurcombe V, Le Bourhis X. FGF singnals for cell proliferation through different pathways. Cytokine Growth Factor Rev 2000;11:295-302.
Han B, Mehra R, Dhanasekaran SM, Yu J, Menon A, Lonigro RJ, Wang X, Gong Y, Wang L, Shankar S, Laxman B, Shah RB, Varambally S, Palanisamy N, Tomlins SA, Kumar-Sinha C, Chinnaiyan AM. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: Identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res 2008;68:7629-7637.
Marker PC, Donjacour AA, Dahiya R, Cunha GR. Hormonal, cellular, and molecular control of prostatic development. Dev Biol 2003;253:165-174.
Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 2002;168:599-604.
Hammarsten J, Ho¨gstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001;39:151-158.
Berger AP, Bartsch G, Deibl M, Alber H, Pachinger O, Fritsche G, Rantner B, Fraedrich G, Pallwein L, Aigner F, Horninger W, Frauscher F. Atherosclerosis as a risk factor for benign prostatic hyperplasia. BJU Int 2006;98:1038-1042.
Crews CM, Erikson RL. Extracellular signals and reversible protein phosphorylation: What to Mek of it all. Cell 1993;74:215-217.
Casalvieri KA, Matheson CJ, Backos DS, Reigan P. Selective Targeting of RSK Isoforms in Cancer. Trends Cancer 2017;3:302-312.
Cruzalegui FH, Cano E, Treisman R. ERK activation induces phosphorylation of Elk-1 at multiple S/T-P motifs to high stoichiometry. Oncogene 1999;18:7948-7957.
O’Neill E, Kolch W. Conferring specificity on the ubiquitous Raf/MEK signalling pathway. Br J Cancer 2004;90:283-288.
Shaul YD, Seger R. The MEK/ERK cascade: From signaling specificity to diverse functions. Biochim Biophys Acta 2007;1773:1213-1226.
Srinivasan K, Patole PS, Kaul CL, Ramarao P. Reversal of glucose intolerance by pioglitazone in high fat diet-fed rats. Methods Find Exp Clin Pharmacol 2004;26:327-333.
- Abstract Viewed: 0 times
- Just Accepted/5694 Downloaded: 0 times